Compare CBU & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBU | LIVN |
|---|---|---|
| Founded | 1866 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 1994 | 2015 |
| Metric | CBU | LIVN |
|---|---|---|
| Price | $62.51 | $63.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $66.67 | ★ $72.43 |
| AVG Volume (30 Days) | 228.5K | ★ 701.7K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ 15.41 | N/A |
| EPS | ★ 3.97 | N/A |
| Revenue | ★ $818,007,000.00 | N/A |
| Revenue This Year | $13.46 | $9.79 |
| Revenue Next Year | $7.75 | $6.89 |
| P/E Ratio | $15.75 | ★ N/A |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $51.02 | $34.00 |
| 52 Week High | $67.50 | $71.58 |
| Indicator | CBU | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 49.80 |
| Support Level | $54.14 | $61.60 |
| Resistance Level | $65.35 | $65.25 |
| Average True Range (ATR) | 1.31 | 2.02 |
| MACD | 0.74 | 0.27 |
| Stochastic Oscillator | 94.83 | 51.02 |
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional and governmental customers. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services and Wealth Management Services.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.